GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adamas Pharmaceuticals Inc (NAS:ADMS) » Definitions » ROE %

Adamas Pharmaceuticals (Adamas Pharmaceuticals) ROE % : 0.00% (As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Adamas Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Adamas Pharmaceuticals's annualized net income for the quarter that ended in Sep. 2021 was $-78.07 Mil. Adamas Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Sep. 2021 was $-12.82 Mil. Therefore, Adamas Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2021 was N/A%.

The historical rank and industry rank for Adamas Pharmaceuticals's ROE % or its related term are showing as below:

During the past 9 years, Adamas Pharmaceuticals's highest ROE % was 230.29%. The lowest was -236.39%. And the median was -43.86%.

ADMS's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 4.225
* Ranked among companies with meaningful ROE % only.

Adamas Pharmaceuticals ROE % Historical Data

The historical data trend for Adamas Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adamas Pharmaceuticals ROE % Chart

Adamas Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROE %
Get a 7-Day Free Trial Premium Member Only -48.36 -90.25 -167.94 -236.39 -

Adamas Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -5,186.55 -

Competitive Comparison of Adamas Pharmaceuticals's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Adamas Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adamas Pharmaceuticals's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adamas Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Adamas Pharmaceuticals's ROE % falls into.



Adamas Pharmaceuticals ROE % Calculation

Adamas Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income (A: Dec. 2020 )/( (Total Stockholders Equity (A: Dec. 2019 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=-57.403/( (-0.893+-49.976)/ 2 )
=-57.403/-25.4345
=N/A %

Adamas Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2021 is calculated as

ROE %=Net Income (Q: Sep. 2021 )/( (Total Stockholders Equity (Q: Jun. 2021 )+Total Stockholders Equity (Q: Sep. 2021 ))/ count )
=-78.072/( (-4.033+-21.606)/ 2 )
=-78.072/-12.8195
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2021) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Adamas Pharmaceuticals  (NAS:ADMS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2021 )
=Net Income/Total Stockholders Equity
=-78.072/-12.8195
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-78.072 / 103.584)*(103.584 / 147.3105)*(147.3105 / -12.8195)
=Net Margin %*Asset Turnover*Equity Multiplier
=-75.37 %*0.7032*N/A
=ROA %*Equity Multiplier
=-53 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2021 )
=Net Income/Total Stockholders Equity
=-78.072/-12.8195
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-78.072 / -78.072) * (-78.072 / -22.544) * (-22.544 / 103.584) * (103.584 / 147.3105) * (147.3105 / -12.8195)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 3.4631 * -21.76 % * 0.7032 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2021) net income data. The Revenue data used here is four times the quarterly (Sep. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Adamas Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Adamas Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1900 Powell Street, Suite 1000, Emeryville, CA, USA, 94608
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
Executives
Vijay Shreedhar officer: Chief Commercial Officer C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608
Christopher B Prentiss officer: Chief Financial Officer 1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608
Anna Richo director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Mardi Dier director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
William W. Ericson director, 10 percent owner 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
John A Macphee director C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Ivan M Lieberburg director 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Neil F. Mcfarlane officer: Chief Executive Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Alfred G Merriweather officer: Chief Financial Officer
Jennifer J Rhodes officer: CBO, GC & Compliance Officer C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Gregory T Went director, officer: Chief Executive Officer C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608
Rajiv Patni officer: Chief Medical Officer C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Headlines